Fortress Biotech, Inc. (NASDAQ:FBIO) Receives Consensus Rating of “Moderate Buy” from Analysts

Fortress Biotech, Inc. (NASDAQ:FBIOGet Rating) has earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.60.

FBIO has been the subject of a number of research analyst reports. B. Riley decreased their price target on Fortress Biotech from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, July 14th. StockNews.com raised Fortress Biotech from a “sell” rating to a “hold” rating in a report on Saturday, September 3rd. Finally, LADENBURG THALM/SH SH started coverage on Fortress Biotech in a report on Thursday, August 4th. They issued a “buy” rating and a $6.00 price objective on the stock.

Fortress Biotech Trading Down 7.7 %

Fortress Biotech stock opened at $0.98 on Tuesday. The stock has a 50-day moving average of $1.05 and a two-hundred day moving average of $1.06. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.70 and a current ratio of 2.85. Fortress Biotech has a one year low of $0.77 and a one year high of $3.81. The stock has a market cap of $105.46 million, a PE ratio of -0.92 and a beta of 2.00.

Institutional Trading of Fortress Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of FBIO. Advisor Group Holdings Inc. grew its holdings in Fortress Biotech by 113.0% during the first quarter. Advisor Group Holdings Inc. now owns 20,020 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 10,620 shares during the period. BNP Paribas Arbitrage SA grew its holdings in Fortress Biotech by 495.0% during the second quarter. BNP Paribas Arbitrage SA now owns 39,636 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 32,974 shares during the period. Envestnet Asset Management Inc. acquired a new stake in Fortress Biotech during the first quarter worth about $33,000. Mirabella Financial Services LLP purchased a new position in Fortress Biotech during the first quarter worth approximately $42,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in Fortress Biotech by 146.9% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 56,142 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 33,399 shares in the last quarter. 28.66% of the stock is owned by institutional investors and hedge funds.

About Fortress Biotech

(Get Rating)

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne.

Featured Stories

Analyst Recommendations for Fortress Biotech (NASDAQ:FBIO)

Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.